Basic Trazodone Information

• INN (International Nonproprietary Name): Trazodone
• Brand Names Available In United Kingdom: Desyrel (listed worldwide), generic trazodone preparations and extended‑release brands marketed in Europe such as Trittico family (availability varies); see international product listings for full brand detail.
• ATC Code: N06AX05
• Forms & Dosages: Immediate‑release tablets commonly 50mg and 100mg; extended‑release/prolonged‑release tablets in 75mg, 100mg and 150mg strengths (marketed as retard/CR/XR formulations in some countries); oral solution is not typically marketed.
• Manufacturers In United Kingdom: Local manufacturers not specified; major world suppliers reported in product registries include Angelini Group, Intas Pharma, Mylan and others that supply the UK market via wholesalers.
• Registration Status In United Kingdom: Registered uses align with EMA/FDA approval for major depressive disorder; prescription‑only medicine (check MHRA/SPC for product‑specific licensing).
• OTC / Rx Classification: Prescription only (Rx).

Major 2022–2025 Studies

Patients and clinicians often ask whether newer trials change how trazodone should be used.

Recent evidence from 2022–2025 mixes older randomised controlled trial data with newer observational and pragmatic studies.

Contemporary research continues to support trazodone’s licence for major depressive disorder at standard antidepressant doses.

More recent pragmatic work and cohort studies have focused on low‑dose nocturnal use for insomnia and on real‑world safety monitoring in older adults.

High‑quality polysomnography trials remain limited, and many sleep studies rely on subjective sleep continuity measures.

Main Outcomes

The strongest evidence still supports antidepressant efficacy at standard doses (typically 75–400mg/day) similar to historical RCT results.

Low doses (25–100mg at night) show consistent short‑term reductions in sleep latency and improved subjective sleep continuity in pragmatic trials.

Effect sizes for insomnia are modest and studies often lack objective sleep staging data.

Real‑world effectiveness for mood disorders remains aligned with SPC recommendations when conventional doses are used.

Overall, trazodone retains a clinical niche for patients needing both mood and sleep benefits.

Safety Observations

Post‑2020 pharmacoepidemiology reports reinforce known safety signals rather than reveal new common harms.

Hyponatraemia, orthostatic hypotension and rare priapism continue to appear in cohort analyses, particularly among older adults and those on multiple medicines.

Dose‑related sedation and fall risk are prominent concerns in geriatrics, with guidance to start low and monitor.

QT prolongation and arrhythmia concerns surface chiefly when trazodone is combined with other QT‑prolonging drugs.

Regulators continue routine pharmacovigilance; insomnia prescribing remains largely off‑label in the UK despite widespread use.

Layman’s Explanation

What does trazodone actually do when someone takes it?

Trazodone is an antidepressant that can also make people sleepier, so it often helps both low mood and poor sleep.

At night it commonly shortens the time it takes to fall asleep and can improve how continuous sleep feels.

People notice its calming and sedating effects more at lower night‑time doses than the higher doses used for depression.

Scientific Breakdown

How trazodone works is a combination of modest serotonin reuptake blockade and receptor antagonism.

Pharmacologically it is classified as a serotonin antagonist and reuptake inhibitor (SARI).

Serotonin Reuptake Inhibition

Trazodone blocks the serotonin transporter (SERT) to a modest degree, which raises synaptic 5‑HT concentrations at antidepressant doses (typical 75–400mg/day).

5‑HT2A/2C Antagonism And H1 Blockade

Potent antagonism at 5‑HT2A and 5‑HT2C receptors reduces anxiety and insomnia and helps mitigate SSRI‑related agitation.

H1 histamine receptor blockade produces sedation that clinicians exploit with night‑time dosing for sleep.

Other Receptors And PK

Alpha‑1 adrenergic antagonism explains orthostatic hypotension and contributes to rare priapism risk.

Hepatic metabolism via CYP pathways (notably CYP3A4 and CYP2D6) and active metabolites influence half‑life and interactions.

In the UK context, check interactions with common CYP substrates such as some macrolide antibiotics, azole antifungals and antidepressants; dose adjustment is advised in hepatic impairment.

United Kingdom Approvals

Many patients want to know what trazodone is officially for in the UK.

Trazodone is approved by regulatory authorities such as the EMA and FDA for major depressive disorder and remains prescription‑only in the UK.

Typical antidepressant dosing per SPCs is 75–400mg/day in divided doses, with higher inpatient doses noted in product information.

Clinicians should follow the SPC and local formularies when treating depression with trazodone.

Notable Off‑Label Trends

Why do people still get trazodone for sleep if it is not licensed for insomnia?

Low‑dose trazodone (25–100mg at bedtime) is widely used off‑label to treat insomnia because of its sedating properties.

Other off‑label uses include adjunctive therapy in chronic pain, anxiety disorders, and behavioural sleep disturbance in dementia, although evidence quality varies.

Where off‑label prescribing occurs, clinicians should document the rationale and monitor for adverse events like hyponatraemia and orthostatic hypotension.

General Dosing

Patients frequently ask how to start trazodone safely.

Begin low and titrate slowly while considering indication, age and hepatic function.

For depression, typical initiation is 75–150mg/day in divided doses with upward titration over 2–4 weeks if needed.

Maximum adult outpatient dosing is usually up to 400mg/day; inpatient product data notes doses up to 600mg/day in select circumstances.

In elderly or hepatic impairment start lower (often 50mg at night) and monitor for sedation and orthostasis.

Condition‑Specific Dosing

What dose is used for each problem?

Major Depressive Disorder

Typical initiation is 75–150mg/day in divided doses, increasing over weeks according to response and tolerability.

Continue treatment for a minimum of six months after remission per SPC guidance.

Insomnia (Off‑Label)

Low doses of 25–100mg at bedtime are commonly used in the UK for short‑term insomnia relief, though this is off‑label and long‑term safety data are limited.

Special Populations

Paediatric use is not established and generally not recommended.

Elderly patients should start at lower doses and be monitored for fall risk and hyponatraemia.

Reduce doses and titrate cautiously in hepatic or severe renal impairment due to potential accumulation.

Contraindications

Before prescribing, clinicians and patients must be clear about absolute exclusions.

Do not use trazodone in patients with known hypersensitivity to the drug or excipients.

It is also contraindicated following a recent myocardial infarction and during acute intoxication with alcohol, hypnotics or other CNS depressants.

Exercise caution in bipolar disorder, seizure disorders, angle‑closure glaucoma and significant hepatic or cardiac disease.

Adverse Effects

Which side effects are most likely and which need urgent attention?

Common adverse effects include sedation, dizziness and orthostatic hypotension, headache, dry mouth, nausea, blurred vision, constipation and fatigue.

More serious but rare effects include priapism (a medical emergency), serotonin syndrome when combined with other serotonergic agents, hyponatraemia/SIADH and arrhythmias, including QT prolongation.

Mitigation involves medication reconciliation for CYP and serotonergic interactions, an ECG if cardiac disease or QT‑prolonging co‑meds are present, and serum sodium checks in elderly or symptomatic patients.

Food Interactions

Patients often ask whether they should avoid certain foods.

No major food‑specific restrictions are listed in the SPC; trazodone may be taken with or without food.

Avoid alcohol, as it increases CNS depression and potentiates sedation and fall risk.

Drug Combinations To Avoid

Which medicines should not be combined with trazodone?

Serotonergic Agents

Avoid MAO inhibitors and use caution when combining trazodone with SSRIs, SNRIs or other serotonergic drugs because of serotonin syndrome risk.

QT‑Prolonging Drugs And Antiarrhythmics

Concomitant use with other QT‑prolonging medicines (certain antipsychotics, macrolides, some fluoroquinolones) increases arrhythmia risk and may require ECG monitoring.

CYP Interactions

Trazodone is metabolised by CYP enzymes, notably CYP3A4 and CYP2D6; potent inhibitors such as some azole antifungals or certain antiretrovirals can raise trazodone levels and may necessitate dose reduction.

CNS Depressants

Combining trazodone with benzodiazepines, opioids or alcohol causes additive sedation; monitor for respiratory depression and impaired alertness.

Survey Data

What do patients report about taking trazodone?

Patient‑reported outcome measures often show improved sleep quality and daytime mood when trazodone is used, particularly where insomnia accompanies depression.

Tolerability is mixed: many appreciate night‑time sedation, while daytime somnolence, dizziness and sexual side effects can prompt discontinuation.

Older adults report higher rates of dizziness and balance problems leading to increased fall risk.

Forum Trends

What are people saying online about trazodone?

Forum discussions commonly praise rapid sleep onset and improved continuity on low night‑time doses, but there are frequent reports of morning grogginess and orthostatic dizziness.

Rare but serious adverse event stories, such as priapism, appear in online anecdote threads and emphasise the need for prompt medical review of alarming symptoms.

Conversations also include practical tips about switching doses and considering immediate versus extended‑release forms.

Distribution & Pricing Landscape

How available is trazodone and what does it cost?

Trazodone is widely available globally in generic and branded forms including Desyrel and various Trittico formulations, with multiple manufacturers supplying the UK market.

Common strengths for immediate‑release tablets are 50mg and 100mg, and extended‑release products are available where licensed.

In the UK trazodone is dispensed via NHS prescriptions where generic pricing typically makes it cost‑effective; brand premiums apply for extended‑release proprietary products.

Pack sizes and availability vary across community pharmacies and hospital formularies, so clinicians should check local supply and consider bioequivalence when substituting brands.

Comparison Table

Clinicians often want a quick sense of how trazodone compares with alternatives.

SSRIs (Sertraline, Escitalopram, Fluoxetine)

Pros: Strong evidence for depression and favourable cardiovascular profile.

Cons: Can initially worsen insomnia and commonly cause sexual dysfunction.

Mirtazapine

Pros: Sedating, useful where depression and insomnia co‑exist, can increase appetite where weight gain is desirable.

Cons: Daytime sedation and weight gain are common.

Doxepin (Low‑Dose)

Pros: Effective for sleep maintenance in some patients.

Cons: Anticholinergic effects and orthostatic hypotension limit use in older adults.

Nefazodone

Pros: A SARI with sedating properties similar to trazodone.

Cons: Restricted by hepatotoxicity concerns and rarely used.

Pros And Cons Summary

Trazodone’s niche is an antidepressant with sedative effects useful when insomnia overlaps with depression.

For isolated insomnia clinicians should consider licensing caveats and evidence; CBT‑I or licensed hypnotics may be preferred first‑line in many cases.

Drug‑interaction profiles, fall risk and hepatic considerations should guide agent selection in UK primary care.

Regulatory Status

Is trazodone approved and where?

Trazodone is classified under ATC code N06AX05 and is approved across Europe, North America and many other regions for major depressive disorder.

It remains prescription‑only in the UK, with product availability and formulations differing between countries.

Extended‑release products have varied regulatory histories; for example, some formulations such as Oleptro have been withdrawn in certain markets while Trittico variants remain available in parts of Europe.

Clinicians should consult the MHRA and the relevant SPC for current indications, contraindications and safety communications.

Rapid Answers For Clinicians & Patients

Q: Is trazodone licensed for insomnia?

A: No. Licence is for major depressive disorder; insomnia dosing (25–100mg at night) is commonly off‑label.

Q: What doses are common?

A: For depression 75–150mg/day up to 400mg/day (inpatient up to 600mg/day). For insomnia 25–100mg at bedtime.

Q: Major safety concerns?

A: Sedation, orthostatic hypotension, hyponatraemia, rare priapism, serotonin syndrome when combined with other serotonergic agents, and QT/arrhythmia risks in vulnerable patients.

Q: Switching or stopping?

A: Taper gradually to reduce withdrawal symptoms and monitor for recurrence of mood or sleep symptoms.

Q: Is it suitable for elderly?

A: Use with caution; start low (often 50mg at night), monitor for falls and check sodium if clinically indicated.

Suggested Infographics

Which visuals help patients and clinicians understand trazodone quickly?

Dosing Flowchart

Flowchart separating depression and insomnia pathways with start, titration and monitoring steps (include SPC dose ranges 25–400mg/day).

Safety Checklist Infographic

One‑page visual showing contraindications, red flags (priapism, severe hypotension, hyponatraemia), and prompts for ECG/CYP interaction checks.

Receptor Action Schematic

Simple diagram showing SERT inhibition, 5‑HT2A/2C antagonism, H1 blockade and alpha‑1 antagonism to explain sedative and orthostatic effects.

Patient Information Card

Downloadable one‑page summary: what to expect, driving advice, alcohol avoidance, missed dose and overdose instructions.

Storage & Transport

How should trazodone be stored and handled in pharmacy practice?

Store at room temperature, generally 15–30°C, in original packaging protected from moisture and light.

Avoid extremes of heat and cold during transport; no pharmaceutical cold‑chain is required for standard tablet forms.

Pharmacists should keep trazodone in secure prescription stock, label with counselling points about sedation and alcohol avoidance, and check packaging integrity for extended‑release tablets.

When substituting brands verify bioequivalence and advise patients on correct administration and home storage (cool, dry place) and safe disposal of unused tablets.

Initiation Checklist

What needs to be done before the first prescription is issued?

Baseline Assessment

Confirm indication (depression vs off‑label insomnia), perform medication reconciliation for serotonergic and QT‑prolonging drugs, review cardiac history, assess liver/renal function and fall risk, and counsel on sedation and alcohol avoidance.

Dose Plan And Documentation

Agree a starting dose (for example 75mg/day divided for depression or 25–100mg at night for insomnia), set a titration schedule and record review dates and expected timelines for antidepressant effect (2–4 weeks).

Ongoing Monitoring

What should be reviewed after initiation?

Safety Follow‑Up

Early review within 1–2 weeks to assess tolerability, monitor serum sodium in elderly or symptomatic patients, consider ECG if cardiac risk exists, and watch for serotonin syndrome or signs of priapism.

Discontinuation

Taper gradually when stopping and ensure continuation for at least six months after remission for depression in line with SPC guidance.

Delivery Across United Kingdom

Alternative Options

What else might be considered instead of trazodone?

Choice depends on the primary problem: depression or isolated insomnia, comorbidity and interaction risks.

SSRIs such as sertraline or escitalopram are first‑line for depression with robust evidence but may worsen sleep initially.

Mirtazapine provides sedation and is useful when weight gain is acceptable, but causes daytime sleepiness and appetite changes.

Low‑dose doxepin is another sleep‑focused option, though anticholinergic effects limit use in older patients.

Nefazodone shares a SARI profile but is seldom used due to hepatotoxicity concerns.

For isolated insomnia consider CBT‑I as the evidence‑based first‑line non‑pharmacological approach before off‑label pharmacotherapy.

Consolidated FAQ

Q: Can trazodone treat both mood and sleep?

A: Yes; at antidepressant doses it treats major depressive disorder and at lower night‑time doses many patients experience improved sleep quality.

Q: How quickly does trazodone act for sleep and mood?

A: Sleep benefits may appear rapidly at night‑time doses; antidepressant effects generally take 2–4 weeks to emerge.

Q: Are there monitoring tests to do while on trazodone?

A: Consider baseline medication reconciliation, ECG when indicated, and serum sodium checks in elderly or symptomatic patients.

Q: What should I do about missed doses?

A: Take the missed dose if remembered unless it is almost time for the next dose; do not double up.

Q: What about overdose?

A: Seek urgent medical help. Symptoms can include drowsiness, vomiting, arrhythmias, respiratory depression, seizures and priapism.

Suggested Infographics

Which charts are most useful to include with this article?

Produce a dosing flowchart, a one‑page safety checklist, a receptor action schematic and a patient information card suitable for download.

Use NHS/MHRA colours for UK audiences and cite the SPC on each visual for traceability.

Storage & Transport

How should patients and pharmacy teams store trazodone at home and in clinics?

Store tablets at room temperature, generally 15–30°C, in original packaging away from moisture and light.

During transport avoid extremes of temperature; standard parcel delivery is appropriate and no cold‑chain is required.

Pharmacies should monitor stock rotation and expiry dates, and verify packaging integrity for extended‑release products since damage may affect release characteristics.

Initiation Protocol

What is the practical checklist to start trazodone safely?

Confirm indication, check other medicines for CYP3A4/CYP2D6 and serotonergic interactions, perform fall risk assessment, review cardiac history and obtain baseline blood tests if clinically indicated.

Document off‑label use when applicable and set an early review appointment for the first 1–2 weeks.

Ongoing Monitoring Schedule

When should follow‑up and tests occur?

Review side effects and efficacy within 1–2 weeks, check serum sodium in elderly or symptomatic patients, and perform ECG if cardiac risk or interacting QT‑prolonging drugs are present.

Plan gradual tapering when discontinuing and continue antidepressant therapy for a minimum of six months after remission for depressive episodes.

Note on Access: In our online pharmacy, trazodone is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

Final Practical Notes

Trazodone remains a well‑established antidepressant with a practical off‑label role for insomnia in low doses.

Use licensed SPC guidance for depression dosing and document clinical justification for any off‑label prescribing.

Prioritise medication reconciliation, fall‑risk assessment and monitoring for hyponatraemia and orthostatic hypotension, especially in older adults.

When combining with other medicines check for CYP interactions and QT‑prolonging drugs and consider ECG or dose adjustment where necessary.

For persistent insomnia, recommend CBT‑I and reassess the need for long‑term pharmacotherapy regularly.